{"id":"https://genegraph.clinicalgenome.org/r/7b3d2915-ca97-4a5f-ab02-b400bf77f115v1.0","type":"EvidenceStrengthAssertion","dc:description":"Primary ciliary dyskinesia (PCD) is a genetically heterogeneous group of disorders, usually beginning in early childhood, characterized by chronic cough, recurrent infections of the upper and lower respiratory tract, randomization of left/right body asymmetry, and subfertility (PMID: 32943623). The PCD phenotype results from structural and/or functional abnormalities of motile cilia and flagella. Ciliary motility is powered by a set of axoneme-specific dynein motor complexes. These large multiprotein complexes are assembled within the cytoplasm by dynein axonemal assembly factors (DNAAFs) before their transport into cilia. Mutations in genes encoding DNAAFs result in the improper cytoplasmic preassembly of dynein chains, causing defects in both inner and outer dynein arms that can result in immotile cilia (PMID: 31624012). The *DNAAF3* (*Dynein Axonemal Assembly Factor 3*) gene was first reported in relation to PCD by Meeks et al. in 2000 as a PCD locus, CILD2, mapped to chromosome 19q13.4 (PMID: 10745040) and was identified and characterized as a cilia related gene (Hs 351852) involved in spermatogenesis by Lin et al. in 2006 (PMID: 17074343). *DNAAF3* (*PF22, C19orf51*) variants were first reported in 2012 by Mitchison et al. (PMID: 22387996). The specific disease entity, primary ciliary dyskinesia 2 is an autosomal recessive disorder caused by homozygous or compound heterozygous mutation in the *DNAAF3* gene. Per criteria outlined by the ClinGen Lumping and Splitting Working Group, we found the molecular mechanism and autosomal recessive mode of inheritance to be consistent among unrelated patients, while the phenotypic variability among them appeared to represent a spectrum of disease rather than separate disease entities. Therefore, cases caused by inherited *DNAAF3* variants have been lumped into a single disease entity, primary ciliary dyskinesia 2 (MONDO: 0011718, OMIM #606763). \n\nEvidence from 18 probands in 5 publications have been included in this curation representing 24 unique variants (5 missense, 5 nonsense, 9 frameshift, 4 splice site, and 1 in-frame delins) (PMIDs: 22387996, 31186518, 32502479, 33577779, 33479112). The mechanism of pathogenicity in *DNAAF3* mutations appears to be bi-allelic loss of function. There is additional case-level evidence available in the literature, but its inclusion in this curation was not necessary to reach the maximum score for genetic evidence (12 points).\n\nOf note, four major isoforms of DNAAF3 are found in NCBIâ€™s RefSeq protein database (PMID: 26553804).  The C-terminal 464 amino acids of these isoforms are identical.  Splicing variants and start codon differences involving the first three exons of the *DNAAF3* gene are responsible for producing 487 (isoform 4), 541 (isoform 3),  588 (isoform 2), and 608 (isoform 1) amino acid proteins.  The MANE Select transcript for *DNAAF3* (NM_001256715.2) is a 2118bp mRNA encoding isoform 3 (PMID: 35388217). There is no published information regarding the significance, if any, of these isoforms in dynein arm assembly or in PCD 2.  Publications used in this gene curation have described pathogenic *DNAAF3* variants in different isoform transcripts. Mitchison et al. (PMID: 22387996) describe variants in isoform 2. Guo et al. and Guan et al. (PMIDs: 31186518, 32502479) describe variants in isoform 1. Shoemark et al. (PMID: 33479112) describe variants in isoform 3. Most of these variants are in the conserved portions of the isoforms, but a few fall in a smaller subset of the isoforms. \n\nThe gene-disease association between PCD 2 and *DNAAF3* is also supported by gene expression data.  GTEx RNA-seq expression studies in reference human tissues show strong expression of *DNAAF3* in lung, testis, and Fallopian tube (PMID: 23715323). This pattern is consistent with the role DNAAF3 is thought to play in the assembly of inner and outer dynein arms in respiratory cilia, sperm flagella, cilia in male efferent ducts, and cilia in Fallopian tubes (PMID: 32943623).  RT-PCR analysis in different human and mouse organs shows expression of *DNAAF3* (HS351582) in human testis and the expression of its mouse ortholog (m247538) in lung, testis, and ovary (PMID: 17074343). The expression of *DNAAF3* in human testis is consistent with the phenotype of male infertility associated with PCD in some patients with *DNAAF3* mutations (PMIDs: 31781811, 22387996).  The expression of murine *Dnaaf3* in mouse lung, testis and ovary parallels the role human DNAAF3 is thought to play in the assembly of inner and outer dynein arms in tissues with motile cilia.\n\nTransmission electron microscopy of cilia cross sections from respiratory epithelial cells of PCD 2 patients (carrying *DNAAF3* mutations) show a loss of both outer and inner dynein arms. Additionally, immunofluorescence to further characterize cilia structure in these cells shows an absence of the outer dynein arm components DNAH5, DNAH9, and DNAI2 and an absence of the inner dynein arm component DNALI1. The absence of these proteins suggests a disruption of outer and inner dynein arm assembly in the airway of these patients. These data are consistent with DNAAF3 assisting in the cytoplasmic assembly of axonemal dynein complexes.\n\nThe cytoplasmic folding and preassembly of dynein arm proteins into larger complexes takes place in a stepwise manner involving interactions with various DNAAFs (PMID: 32943623), chaperones, and co-chaperones (PMID: 31817850). Laser scanning confocal microscopy was used in conjunction with a 3D object-based co-localization algorithm to show that in *Xenopus* embryos DNAAFs concentrate together with axonemal dyneins and chaperones into particles (DynAPs) that form specifically in multiciliated cells (PMID: 30561330). The colocalization of GFP-Dnaaf3 fusion protein with Cherry-Dnaaf2 at DynAPs is consistent with DNAAF3 playing a role in the multistep pathway that assembles inner and outer dynein arm components.\n\nSeveral animal models have been used to understand and support the gene-disease relationship between *DNAAF3* and PCD 2. The *Chlamydomonas* PF22-null mutant carries a mutation in *DAB1* (*PF22*), the *Chlamydomonas* ortholog of *DNAAF3* (PMID: 22387996). This mutant exhibits a phenotype of short flagella, lack of motility and dynein assembly defects, a phenotype consistent with ciliary defects seen in PCD 2. Transformation of pf22 mutant *Chlamydomonas* with wild type copies of *pf22* rescues the pf22 phenotype. Morpholino knockdown of *dnaaf3* in zebrafish similarly disrupts dynein arm assembly and ciliary motility causing phenotypes that include hydrocephalus and laterality defects (PMID: 22387996). While laterality defects are frequently associated with *DNAAF3* mutations in human PCD (PMID: 22387996), hydrocephalus has not been reported as a phenotype for PCD 2 but has been associated with a small subset of other PCD gene mutations (PMID: 32943623). RNAi knockdown and CRISPR/Cas9 knockout of *Drosophila* *Dnaaf3* produce flies that exhibit phenotypes consistent with ciliary/flagellar immotility with loss of both outer and inner dynein arms, and depletion of dynein heavy chains in mutant cilia (PMID: 34553759). Male infertility, immotile sperm, and the loss of auditory/vibration mechanotransduction in Ch neurons in *Drosophila* *Dnaaf3* knockouts are phenotypes consistent with the human *DNAAF3* mutations that result in immotile cilia in multiciliated cells.  \n\nIn summary, there is definitive evidence supporting a gene-disease relationship between variants in *DNAAF3* and primary ciliary dyskinesia 2. This has been repeatedly demonstrated in both research and clinical diagnostic settings, and has been upheld over time. This classification was approved by the ClinGen Motile Ciliopathy GCEP on May 6, 2022  (SOP Version 8).\n","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/7b3d2915-ca97-4a5f-ab02-b400bf77f115","GCISnapshot":"https://genegraph.clinicalgenome.org/r/40329b6f-2d65-49dd-863b-f79dcd1b5a23","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/40329b6f-2d65-49dd-863b-f79dcd1b5a23_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10102","date":"2022-05-09T15:56:00.823Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/40329b6f-2d65-49dd-863b-f79dcd1b5a23_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10102","date":"2022-05-09T15:57:19.679Z","role":"Publisher"}],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/40329b6f-2d65-49dd-863b-f79dcd1b5a23_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a3bdbf5a-430c-4fbe-8f20-47a450473626_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f7be08b7-debc-4542-be3a-429a6a16357e","type":"EvidenceLine","calculatedScore":0.2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f7be08b7-debc-4542-be3a-429a6a16357e_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NC_000019.10:g.55161826C>T is a splice site mutation in intron 4 of the DNAAF3 gene, predicted by the SplceA1 algorithm to disrupt the essential acceptor splice site at the highly conserved G residue.","functionalDataSupport":"No"},{"id":"https://genegraph.clinicalgenome.org/r/f7be08b7-debc-4542-be3a-429a6a16357e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33479112","allele":{"id":"https://genegraph.clinicalgenome.org/r/bffb118d-b27c-4352-ae51-133eb8aa72c4","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000019.10:g.55161826C>T (GRCh38)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA407456251"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/a3bdbf5a-430c-4fbe-8f20-47a450473626","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33479112","rdfs:label":"01-112","allele":{"id":"https://genegraph.clinicalgenome.org/r/bffb118d-b27c-4352-ae51-133eb8aa72c4"},"detectionMethod":"Next-generation sequencing performed either by whole exome sequencing (WES) or targeted gene panel sequencing (Illumina TruSeq Custom Amplicon, Agilent SureSelect Focused Exome or SureSelectXT custom panel), including all known PCD genes and other candidate genes.\n\nVariants were confirmed by Sanger sequencing with parental segregation. For a number of patients, variants were identified by candidate gene Sanger sequencing.","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"DNAAF3 variant patients in this study were stratified into a group comprised of other patients with variants in genes that are involved in dynein assembly. As a group, these patients share diagnostic characteristics including: decreased nasal nitric oxide, ODA and IDA defects, microtubule disorganization, lack of cilia, and immotile or stiff cilia. Some of these characteristics may not be specific to DNAAF3.","previousTesting":false,"secondTestingMethod":"Next generation sequencing panels","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/f7be08b7-debc-4542-be3a-429a6a16357e_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/e88c9d48-1928-4c2a-b69b-eb35beb04d96_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/de548a0a-35aa-4365-bd0e-0e0c217e4149","type":"EvidenceLine","dc:description":"Down-scored for homozygosity","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/de548a0a-35aa-4365-bd0e-0e0c217e4149_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_001256715.2(DNAAF3):c.901C>T is a nonsense mutation predicted to replace Gln 301 with a termination signal, prematurely truncating 44% of the protein product or triggering nonsense-mediated decay. ","functionalDataSupport":"No"},{"id":"https://genegraph.clinicalgenome.org/r/de548a0a-35aa-4365-bd0e-0e0c217e4149_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33479112","allele":{"id":"https://genegraph.clinicalgenome.org/r/470160ce-1239-4d7a-90ef-0018042f0494","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001256715.2(DNAAF3):c.901C>T (p.Gln301Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA407452085"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/e88c9d48-1928-4c2a-b69b-eb35beb04d96","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33479112","rdfs:label":"01-131","allele":{"id":"https://genegraph.clinicalgenome.org/r/470160ce-1239-4d7a-90ef-0018042f0494"},"detectionMethod":"Next-generation sequencing performed either by whole exome sequencing (WES) or targeted gene panel sequencing (Illumina TruSeq Custom Amplicon, Agilent SureSelect Focused Exome or SureSelectXT custom panel), including all known PCD genes and other candidate genes.\n\nVariants were confirmed by Sanger sequencing with parental segregation. For a number of patients, variants were identified by candidate gene Sanger sequencing.","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"DNAAF3 variant patients in this study were stratified into a group comprised of other patients with variants in genes that are involved in dynein assembly. As a group, these patients share diagnostic characteristics including: decreased nasal nitric oxide, ODA and IDA defects, microtubule disorganization, lack of cilia, and immotile or stiff cilia. Some of these characteristics may not be specific to DNAAF3.","previousTesting":false,"secondTestingMethod":"Next generation sequencing panels","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/de548a0a-35aa-4365-bd0e-0e0c217e4149_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/8827e620-4fd8-4df5-8c42-2e1bb797afca_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2b123560-4558-4781-abd5-9650046f7aae","type":"EvidenceLine","dc:description":"This variant has been down-scored to 0.5 because of parental consanguinity and homozygosity of the variant in the proband. It has been further down-scored to 0.25 because the genotyping method was Sanger sequencing and mutations in other PCD genes were not excluded.","calculatedScore":4,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2b123560-4558-4781-abd5-9650046f7aae_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_001256715.2(DNAAF3):c.182T>C, referred to by authors as NM_178837.4:c.323T>C (NP_849159.2:p.Leu108Pro), is a missense mutation predicted to replace Leu108 with a Pro. This Leu residue is highly conserved across ciliated species. Polyphen-2 and SIFT analysis predict a substitution of Pro for Leu108 is damaging. Expression (immunofluorescent antibody studies) of ODA and IDA proteins, DNAH5, DNAH9, DNAI2 and DNALI1, respectively, were studied in nasal respiratory cells from this individual. Both ODA proteins and IDA proteins were absent suggesting that DNAAF3 is key for the assembly of ODA and IDA along the entire length of the axoneme.  Electron microscopy confirmed the absence of ODAs and IDAs.  Respiratory cilia were immotile","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/2b123560-4558-4781-abd5-9650046f7aae_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22387996","allele":{"id":"https://genegraph.clinicalgenome.org/r/15abaf4f-a81f-4c97-9ec7-0299435735f0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001256715.2(DNAAF3):c.182T>C (p.Leu61Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA025062"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/8827e620-4fd8-4df5-8c42-2e1bb797afca","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22387996","rdfs:label":"UCL89-IV.2","allele":{"id":"https://genegraph.clinicalgenome.org/r/15abaf4f-a81f-4c97-9ec7-0299435735f0"},"detectionMethod":"All 12 coding exons of DNAAF3 were amplified from genomic DNA.  PCD families were also SNP haplotyped across the DNAAF3 locus. ","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Linkage analysis","phenotypes":["obo:HP_0012259","obo:HP_0012735","obo:HP_0100582","obo:HP_0002110","obo:HP_0012263","obo:HP_0000388","obo:HP_0003251","obo:HP_0002643","obo:HP_0012208","obo:HP_0031417","obo:HP_0000246","obo:HP_0002783","obo:HP_0030828"],"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/2b123560-4558-4781-abd5-9650046f7aae_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/039ff1d0-ae0c-4326-8e86-3bc9e82fbb24_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/db1fada3-5b5e-4c58-902d-a5c7f18d2f03","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/db1fada3-5b5e-4c58-902d-a5c7f18d2f03_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_001256715.2(DNAAF3):c.59C>A, referred to by authors as NM_001256714.1:c.200C>A (NP_001243643.1:p.Ser67Tyr),  is a missense mutation predicted to change Ser67 to Tyr.  This alteration is predicted to be deleterious by PROVEAN and Polyphen-2 protein function predictors.  This particular variation is predicted to be found only in isoforms 1, 2, and 3 (NP_001243643.1, NP_849159.2, NP_001243644.1) of DNAAF3 but not in isoform 4. RT-PCR of proband RNA from nasal epithelial cells confirmed the presence of variant cDNA in this individual.  This variant is not found in gnomAD. TEM of respiratory cell cilia to view dynein arms confirmed the absence of ODA and IDA. HSVA showed immotile cilia. ","functionalDataSupport":"No"},{"id":"https://genegraph.clinicalgenome.org/r/db1fada3-5b5e-4c58-902d-a5c7f18d2f03_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31186518","allele":{"id":"https://genegraph.clinicalgenome.org/r/191182d0-2334-4533-931d-8daf37e60249","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001256715.2(DNAAF3):c.59C>A (p.Ser20Tyr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA407463108"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/4ff9760e-2cdd-46a4-bb76-ce7b6743c1ca","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4ff9760e-2cdd-46a4-bb76-ce7b6743c1ca_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_001256715.2(DNAAF3):c.607_611dup, referred to by authors as NM_001256714.1:c.811_815dup (NP_001243643.1:p.Arg273ThrfsTer13),  is a frameshift mutation caused by a 5bp duplication.  This variant is predicted to replace Arg273 with Thr and introduce a termination 13 amino acids downstream, truncating the protein product by 62% or triggering non-sense mediated decay. RT-PCR of proband RNA from nasal epithelial cells confirmed the presence of variant cDNA in this individual.  TEM of respiratory cell cilia to view dynein arms confirmed the absence of ODA and IDA. HSVA showed immotile cilia. ","functionalDataSupport":"No"},{"id":"https://genegraph.clinicalgenome.org/r/4ff9760e-2cdd-46a4-bb76-ce7b6743c1ca_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31186518","allele":{"id":"https://genegraph.clinicalgenome.org/r/704d7b8e-b646-4ba9-9903-7896750f7481","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001256715.2(DNAAF3):c.607_611dup (p.Arg205fs)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA16616432"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/039ff1d0-ae0c-4326-8e86-3bc9e82fbb24","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31186518","rdfs:label":"P3 (IV-2)","ageType":"AgeAtReport","ageUnit":"Months","ageValue":16,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/704d7b8e-b646-4ba9-9903-7896750f7481"},{"id":"https://genegraph.clinicalgenome.org/r/191182d0-2334-4533-931d-8daf37e60249"}],"detectionMethod":"Sanger sequencing was conducted to validate candidate variants identified by WES and segregation analysis was performed in available family members.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0012263","obo:HP_0000246","obo:HP_0012259","obo:HP_0031245","obo:HP_0033036","obo:HP_0001696","obo:HP_0002643"],"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":[{"id":"https://genegraph.clinicalgenome.org/r/db1fada3-5b5e-4c58-902d-a5c7f18d2f03_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/4ff9760e-2cdd-46a4-bb76-ce7b6743c1ca_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.6},{"id":"https://genegraph.clinicalgenome.org/r/2591094c-5ce6-4999-83d9-a9b57f1dbddf_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/eea7acdc-a13d-40cd-bdc5-689e929ade1d","type":"EvidenceLine","dc:description":"Down-scored due to homozygosity and consanguinity","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/eea7acdc-a13d-40cd-bdc5-689e929ade1d_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_001256715.2(DNAAF3):c.475del, referred to by authors as NM_001256714.1:c.679del (NP_001243643.1:p.Leu227SerfsTer28), is a frameshift mutation predicted to replace Leu227 with Ser and a termination signal 28 amino acids downstream, producing a 71% truncated protein product or triggering nonsense-mediated decay.  TEM of respiratory cell cilia to view dynein arms confirmed the absence of ODA and IDA. HSVA showed immotile cilia.","functionalDataSupport":"No"},{"id":"https://genegraph.clinicalgenome.org/r/eea7acdc-a13d-40cd-bdc5-689e929ade1d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31186518","allele":{"id":"https://genegraph.clinicalgenome.org/r/adfede6e-db0a-4264-9346-480a80304902","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001256715.2(DNAAF3):c.475del (p.Leu159SerfsTer28)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2573051078"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/2591094c-5ce6-4999-83d9-a9b57f1dbddf","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31186518","rdfs:label":"P2 (IV-3)","ageType":"AgeAtReport","ageUnit":"Months","ageValue":20,"allele":{"id":"https://genegraph.clinicalgenome.org/r/adfede6e-db0a-4264-9346-480a80304902"},"detectionMethod":"Sanger sequencing was conducted to validate candidate variants identified by WES and segregation analysis was performed in available family members.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0012259","obo:HP_0000365","obo:HP_0012735","obo:HP_0000246","obo:HP_0001696","obo:HP_0012387","obo:HP_0033036","obo:HP_0002643","obo:HP_0012263","obo:HP_0030828"],"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/eea7acdc-a13d-40cd-bdc5-689e929ade1d_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/4cfd5099-92e3-443e-bf1e-e23dfcef511c_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8ad4e8c0-a267-4493-bee5-a850bdb39ab4","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8ad4e8c0-a267-4493-bee5-a850bdb39ab4_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_001256715.2(DNAAF3):c.296del is a frameshift mutation predicted to replace Glu 99 with Gly and a termination signal 88 amino acids downstream, prematurely truncating 82% of the protein product or triggering nonsense-mediated decay.  ","functionalDataSupport":"No"},{"id":"https://genegraph.clinicalgenome.org/r/8ad4e8c0-a267-4493-bee5-a850bdb39ab4_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33479112","allele":{"id":"https://genegraph.clinicalgenome.org/r/e04364de-1712-4f20-b832-1e9af259b124","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001256715.2(DNAAF3):c.296del (p.Glu99GlyfsTer88)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2573051128"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/e1df836e-4617-4ad0-a695-d95bd34c0976","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e1df836e-4617-4ad0-a695-d95bd34c0976_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_001256715.2(DNAAF3):c.609_610delinsTGGGA is an in-frame delins mutation that replaces Ala 204 with GlyThr.  The Provean  algorithm predicts that this alteration in DNAAF3 is deleterious.","functionalDataSupport":"No"},{"id":"https://genegraph.clinicalgenome.org/r/e1df836e-4617-4ad0-a695-d95bd34c0976_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33479112","allele":{"id":"https://genegraph.clinicalgenome.org/r/3512575c-e595-4481-b49a-f9e5af1c07ea","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001256715.2(DNAAF3):c.609_610delinsTGGGA (p.Ala204delinsGlyThr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2573051127"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/4cfd5099-92e3-443e-bf1e-e23dfcef511c","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33479112","rdfs:label":"01-047","allele":[{"id":"https://genegraph.clinicalgenome.org/r/3512575c-e595-4481-b49a-f9e5af1c07ea"},{"id":"https://genegraph.clinicalgenome.org/r/e04364de-1712-4f20-b832-1e9af259b124"}],"detectionMethod":"Next-generation sequencing performed either by whole exome sequencing (WES) or targeted gene panel sequencing (Illumina TruSeq Custom Amplicon, Agilent SureSelect Focused Exome or SureSelectXT custom panel), including all known PCD genes and other candidate genes.\n\nVariants were confirmed by Sanger sequencing with parental segregation. For a number of patients, variants were identified by candidate gene Sanger sequencing.","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"DNAAF3 variant patients in this study were stratified into a group comprised of other patients with variants in genes that are involved in dynein assembly. As a group, these patients share diagnostic characteristics including: decreased nasal nitric oxide, ODA and IDA defects, microtubule disorganization, lack of cilia, and immotile or stiff cilia. Some of these characteristics may not be specific to DNAAF3.","previousTesting":false,"secondTestingMethod":"Next generation sequencing panels","sex":"UnknownEthnicity","variant":[{"id":"https://genegraph.clinicalgenome.org/r/8ad4e8c0-a267-4493-bee5-a850bdb39ab4_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/e1df836e-4617-4ad0-a695-d95bd34c0976_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.6},{"id":"https://genegraph.clinicalgenome.org/r/8fe0e197-3c21-4909-80a2-c97fd5933b2e_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/24d0bc4a-5eea-45d6-84fa-8ac270c363ab","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/24d0bc4a-5eea-45d6-84fa-8ac270c363ab_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_001256715.2(DNAAF3):c.353G>A, referred to by authors as NM_001256714.1:c.557G>A (NP_001243643.1:p.Gly186Glu),  is a missense mutation that is predicted to change Gly186 to Glu. This alteration is predicted to be deleterious by PROVEAN and Polyphen-2 protein function predictors. TEM of respiratory cell cilia to view dynein arms confirmed the absence of ODA and IDA. HSVA showed immotile cilia.","functionalDataSupport":"No"},{"id":"https://genegraph.clinicalgenome.org/r/24d0bc4a-5eea-45d6-84fa-8ac270c363ab_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32502479","allele":{"id":"https://genegraph.clinicalgenome.org/r/f3894fea-db60-411b-8e2c-590bae1c795e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001256715.2(DNAAF3):c.353G>A (p.Gly118Glu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA407458163"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/3b64a5c1-4739-42e3-aab0-e86f15803c5b","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3b64a5c1-4739-42e3-aab0-e86f15803c5b_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_001256715.2(DNAAF3):c.826G>T, referred to by authors as NM_001256714.1:c.1030G>T\t(NP_001243643.1:p.Asp344Tyr), is a missense mutation that is predicted to change Asp344 to Tyr. This alteration is predicted to be deleterious by PROVEAN and Polyphen-2 protein function predictors. TEM of respiratory cell cilia to view dynein arms confirmed the absence of ODA and IDA. HSVA showed immotile cilia.","functionalDataSupport":"No"},{"id":"https://genegraph.clinicalgenome.org/r/3b64a5c1-4739-42e3-aab0-e86f15803c5b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32502479","allele":{"id":"https://genegraph.clinicalgenome.org/r/2c38c4cb-435c-4856-9822-f3b06a5f4023","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001256715.2(DNAAF3):c.826G>T (p.Asp276Tyr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA407452705"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/8fe0e197-3c21-4909-80a2-c97fd5933b2e","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32502479","rdfs:label":"P43","ageType":"AgeAtReport","ageUnit":"Years","ageValue":3,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/f3894fea-db60-411b-8e2c-590bae1c795e"},{"id":"https://genegraph.clinicalgenome.org/r/2c38c4cb-435c-4856-9822-f3b06a5f4023"}],"detectionMethod":"Segregation analyses were performed in family members","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0033036","obo:HP_0001696","obo:HP_0012263","obo:HP_0002643","obo:HP_0031245","obo:HP_0000246","obo:HP_0012259","obo:HP_0000389"],"previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":[{"id":"https://genegraph.clinicalgenome.org/r/24d0bc4a-5eea-45d6-84fa-8ac270c363ab_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/3b64a5c1-4739-42e3-aab0-e86f15803c5b_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/8ced7fdc-4827-497c-b46b-891269e99de3_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/74abcd71-f24b-4b5f-8c32-c5371cafed19","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/74abcd71-f24b-4b5f-8c32-c5371cafed19_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_001256715.2(DNAAF3):c.1030_1031delinsG is a frameshift mutation predicted to replace Pro 244 with Gly and a termination signal 64 amino acids downstream, prematurely truncating 36% of the protein product or triggering nonsense-mediated decay.  ","functionalDataSupport":"No"},{"id":"https://genegraph.clinicalgenome.org/r/74abcd71-f24b-4b5f-8c32-c5371cafed19_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33479112","allele":{"id":"https://genegraph.clinicalgenome.org/r/ba3e897f-8b01-4dc9-8357-00ad8f007149","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001256715.2(DNAAF3):c.1030_1031delinsG (p.Pro344GlyfsTer64)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2573051125"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/c1b6a402-2df6-464f-9e6c-31f2be2e335f","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c1b6a402-2df6-464f-9e6c-31f2be2e335f_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_001256715.2(DNAAF3):c.1273G>T is a nonsense mutation predicted to replace Gly 425 with a termination signal, prematurely truncating 21% of the protein product or triggering nonsense-mediated decay. ","functionalDataSupport":"No"},{"id":"https://genegraph.clinicalgenome.org/r/c1b6a402-2df6-464f-9e6c-31f2be2e335f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33479112","allele":{"id":"https://genegraph.clinicalgenome.org/r/4d4d17eb-8dad-4b4b-9a4a-71b1b03699e5","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001256715.2(DNAAF3):c.1273G>T (p.Gly425Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA407447763"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/8ced7fdc-4827-497c-b46b-891269e99de3","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33479112","rdfs:label":"01-186","allele":[{"id":"https://genegraph.clinicalgenome.org/r/ba3e897f-8b01-4dc9-8357-00ad8f007149"},{"id":"https://genegraph.clinicalgenome.org/r/4d4d17eb-8dad-4b4b-9a4a-71b1b03699e5"}],"detectionMethod":"Next-generation sequencing performed either by whole exome sequencing (WES) or targeted gene panel sequencing (Illumina TruSeq Custom Amplicon, Agilent SureSelect Focused Exome or SureSelectXT custom panel), including all known PCD genes and other candidate genes.\n\nVariants were confirmed by Sanger sequencing with parental segregation. For a number of patients, variants were identified by candidate gene Sanger sequencing.","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"DNAAF3 variant patients in this study were stratified into a group comprised of other patients with variants in genes that are involved in dynein assembly. As a group, these patients share diagnostic characteristics including: decreased nasal nitric oxide, ODA and IDA defects, microtubule disorganization, lack of cilia, and immotile or stiff cilia. Some of these characteristics may not be specific to DNAAF3.","previousTesting":false,"secondTestingMethod":"Next generation sequencing panels","sex":"UnknownEthnicity","variant":[{"id":"https://genegraph.clinicalgenome.org/r/c1b6a402-2df6-464f-9e6c-31f2be2e335f_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/74abcd71-f24b-4b5f-8c32-c5371cafed19_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/987c3405-d5ee-4cd0-8627-4cde130bb180_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3e4e32d8-8bb5-4142-9dc4-45eb722ed4db","type":"EvidenceLine","dc:description":"Not scored because proband 01-089 is included in the DNAAF3 study by Mitchison et al, 2012 (PMID: 22387996) and its homozygous variant has already been scored as a homozygous mutation in proband UCL71-IV.2 .","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3e4e32d8-8bb5-4142-9dc4-45eb722ed4db_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_001256715.2(DNAAF3):c.621dup is a frameshift mutation predicted to replace Val 208 with Cys and a termination signal 12 amino acids downstream, prematurely truncating 62% of the protein product or triggering nonsense-mediated decay.  \n","functionalDataSupport":"No"},{"id":"https://genegraph.clinicalgenome.org/r/3e4e32d8-8bb5-4142-9dc4-45eb722ed4db_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33479112","allele":{"id":"https://genegraph.clinicalgenome.org/r/2d020b0f-db64-493f-945a-77cd7408de54","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001256715.2(DNAAF3):c.621dup (p.Val208fs)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA025071"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/987c3405-d5ee-4cd0-8627-4cde130bb180","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33479112","rdfs:label":"01-089","allele":{"id":"https://genegraph.clinicalgenome.org/r/2d020b0f-db64-493f-945a-77cd7408de54"},"detectionMethod":"Next-generation sequencing performed either by whole exome sequencing (WES) or targeted gene panel sequencing (Illumina TruSeq Custom Amplicon, Agilent SureSelect Focused Exome or SureSelectXT custom panel), including all known PCD genes and other candidate genes.\n\nVariants were confirmed by Sanger sequencing with parental segregation. For a number of patients, variants were identified by candidate gene Sanger sequencing.","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"DNAAF3 variant patients in this study were stratified into a group comprised of other patients with variants in genes that are involved in dynein assembly. As a group, these patients share diagnostic characteristics including: decreased nasal nitric oxide, ODA and IDA defects, microtubule disorganization, lack of cilia, and immotile or stiff cilia. Some of these characteristics may not be specific to DNAAF3.","previousTesting":false,"secondTestingMethod":"Next generation sequencing panels","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/3e4e32d8-8bb5-4142-9dc4-45eb722ed4db_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/b9b7a69f-83a3-4405-9b2b-e12607d4236a_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e83ce46d-75fc-4082-a999-d404b56321ae","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e83ce46d-75fc-4082-a999-d404b56321ae_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_001256715.2(DNAAF3):c.839G>A, referred to by authors as NM_001256714.1:c.1043G>A\t(NP_001243643.1:p.Gly348Glu), is a missense mutation predicted to replace Gly348 with Glu. Provean and PolyPhen algorithms predict this alteration to be deleterious.","functionalDataSupport":"No"},{"id":"https://genegraph.clinicalgenome.org/r/e83ce46d-75fc-4082-a999-d404b56321ae_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33577779","allele":{"id":"https://genegraph.clinicalgenome.org/r/48585d45-166c-4b1f-8b91-702a441b8b05","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001256715.2(DNAAF3):c.839G>A (p.Gly280Glu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA407452618"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/28ae24bc-f370-40f6-a332-c38177c3a93f","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/28ae24bc-f370-40f6-a332-c38177c3a93f_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_001256715.2(DNAAF3):c.606_609dup, referred to by authors as NM_001256714.1:c.810_813dup (NP_001243643.1:p.Ala272ArgfsTer17), is a frameshift mutation predicted to replace Ala272 with Arg and a termination signal 17 amino acids downstream, prematurely truncating 62% of the protein product or triggering nonsense-mediated decay.  \n","functionalDataSupport":"No"},{"id":"https://genegraph.clinicalgenome.org/r/28ae24bc-f370-40f6-a332-c38177c3a93f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33577779","allele":{"id":"https://genegraph.clinicalgenome.org/r/4bf271c8-b4bf-4d46-9232-6ee36d1f9893","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001256715.2(DNAAF3):c.606_609dup (p.Ala204ArgfsTer17)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2573051115"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/b9b7a69f-83a3-4405-9b2b-e12607d4236a","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33577779","rdfs:label":"P10","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":11,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/4bf271c8-b4bf-4d46-9232-6ee36d1f9893"},{"id":"https://genegraph.clinicalgenome.org/r/48585d45-166c-4b1f-8b91-702a441b8b05"}],"ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0033036","obo:HP_0002643","obo:HP_0100750","obo:HP_0002110","obo:HP_0031245","obo:HP_0000246","obo:HP_0002099","obo:HP_0012259"],"previousTesting":false,"sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/28ae24bc-f370-40f6-a332-c38177c3a93f_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/e83ce46d-75fc-4082-a999-d404b56321ae_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.6},{"id":"https://genegraph.clinicalgenome.org/r/40329b6f-2d65-49dd-863b-f79dcd1b5a23_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9c0ec462-db73-4f24-a263-4c34c5624ae5_proband_segregation","type":"FamilyCosegregation","dc:description":"Not enough affected individuals or tested unaffected individuals to calculate a LOD score","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31186518","rdfs:label":"Family 4","family":{"id":"https://genegraph.clinicalgenome.org/r/9c0ec462-db73-4f24-a263-4c34c5624ae5","type":"Family","rdfs:label":"Family 4","ethnicity":{"id":"cg:NotHispanicOrLatino"},"member":{"id":"https://genegraph.clinicalgenome.org/r/e7c861de-a850-4ff0-866e-a0bbcad5f63b","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31186518","rdfs:label":"P4 (IV-2)","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":10,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/704d7b8e-b646-4ba9-9903-7896750f7481"},{"id":"https://genegraph.clinicalgenome.org/r/9912cf01-601e-4c4d-b422-1593c29b4d1c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000019.10:g.55165798_55165902del (GRCh38)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2573051089"}}],"detectionMethod":"Sanger sequencing was conducted to validate candidate variants identified by WES and segregation analysis was performed in available family members.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0002643","obo:HP_0012735","obo:HP_0000246","obo:HP_0012263","obo:HP_0012259","obo:HP_0002110","obo:HP_0001696","obo:HP_0006532"],"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":[{"id":"https://genegraph.clinicalgenome.org/r/e9861c3a-e89e-44e0-8db6-86cbe19285a2_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31186518","allele":{"id":"https://genegraph.clinicalgenome.org/r/9912cf01-601e-4c4d-b422-1593c29b4d1c"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"}},{"id":"https://genegraph.clinicalgenome.org/r/06e4bdbe-3659-49d8-8e9a-bf2e53ce5525_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31186518","allele":{"id":"https://genegraph.clinicalgenome.org/r/704d7b8e-b646-4ba9-9903-7896750f7481"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"}}]}},"phenotypePositiveAllelePositive":1,"phenotypes":["obo:HP_0012259","obo:HP_0001696","obo:HP_0002643","obo:HP_0000246","obo:HP_0033036","obo:HP_0012263"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/e7c861de-a850-4ff0-866e-a0bbcad5f63b"}},{"id":"https://genegraph.clinicalgenome.org/r/c45dd406-b1ef-4083-bd9b-5438d3f29722_proband_segregation","type":"FamilyCosegregation","dc:description":"Fewer than 3 affected individuals in this family and no unaffected individuals with testing","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31186518","rdfs:label":"Family 3","family":{"id":"https://genegraph.clinicalgenome.org/r/c45dd406-b1ef-4083-bd9b-5438d3f29722","type":"Family","rdfs:label":"Family 3","ethnicity":{"id":"cg:NotHispanicOrLatino"},"member":{"id":"https://genegraph.clinicalgenome.org/r/039ff1d0-ae0c-4326-8e86-3bc9e82fbb24"}},"phenotypeNegativeAlleleNegative":0,"phenotypePositiveAllelePositive":1,"phenotypes":["obo:HP_0001696","obo:HP_0000246","obo:HP_0002643","obo:HP_0012259","obo:HP_0033036","obo:HP_0012263"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/039ff1d0-ae0c-4326-8e86-3bc9e82fbb24"}},{"id":"https://genegraph.clinicalgenome.org/r/5871bbca-de04-48d8-b893-a1395b577b6f_proband_segregation","type":"FamilyCosegregation","dc:description":"Fewer than 3 affected individuals in this family pedigree and no tested unaffected individuals.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31186518","rdfs:label":"Family 2","family":{"id":"https://genegraph.clinicalgenome.org/r/5871bbca-de04-48d8-b893-a1395b577b6f","type":"Family","rdfs:label":"Family 2","ethnicity":{"id":"cg:NotHispanicOrLatino"},"member":{"id":"https://genegraph.clinicalgenome.org/r/2591094c-5ce6-4999-83d9-a9b57f1dbddf"}},"phenotypePositiveAllelePositive":1,"phenotypes":["obo:HP_0000246","obo:HP_0002643","obo:HP_0012263","obo:HP_0012259","obo:HP_0033036","obo:HP_0001696"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/2591094c-5ce6-4999-83d9-a9b57f1dbddf"}},{"id":"https://genegraph.clinicalgenome.org/r/80e8e6be-91a3-4187-92ca-91e62362ef9a_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22387996","rdfs:label":"UCL89","estimatedLodScore":2.06,"family":{"id":"https://genegraph.clinicalgenome.org/r/80e8e6be-91a3-4187-92ca-91e62362ef9a","type":"Family","rdfs:label":"UCL89","ethnicity":{"id":"cg:NotHispanicOrLatino"},"member":{"id":"https://genegraph.clinicalgenome.org/r/8827e620-4fd8-4df5-8c42-2e1bb797afca"}},"meetsInclusionCriteria":true,"phenotypeNegativeAlleleNegative":2,"phenotypePositiveAllelePositive":4,"phenotypes":["obo:HP_0012263","obo:HP_0006535","obo:HP_0031417","obo:HP_0002110","obo:HP_0100582","obo:HP_0012208","obo:HP_0001696","obo:HP_0002783","obo:HP_0000388","obo:HP_0000246","obo:HP_0012259","obo:HP_0003251","obo:HP_0002643","obo:HP_0012735","obo:HP_0030828"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/8827e620-4fd8-4df5-8c42-2e1bb797afca"},"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/c3ec83a9-db62-4597-bc71-ef3124f7d14a_proband_segregation","type":"FamilyCosegregation","dc:description":"Fewer than 3 affected individuals in family pedigree and no tested unaffected individuals.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31186518","rdfs:label":"Family 1","family":{"id":"https://genegraph.clinicalgenome.org/r/c3ec83a9-db62-4597-bc71-ef3124f7d14a","type":"Family","rdfs:label":"Family 1","ethnicity":{"id":"cg:NotHispanicOrLatino"},"member":{"id":"https://genegraph.clinicalgenome.org/r/c9fd6ff8-b0b3-4883-b298-b0f81fa381bf","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31186518","rdfs:label":"P1 (IV-2)","ageType":"AgeAtReport","ageUnit":"Years","ageValue":11,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/017eaa29-9f0d-4741-b511-cb5cc36db837","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001256715.2(DNAAF3):c.238del (p.Leu80TrpfsTer13)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2573051077"}},{"id":"https://genegraph.clinicalgenome.org/r/f10265d7-a1fa-4abd-90da-fbf69c3480a8","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001256715.2(DNAAF3):c.1264C>T (p.Gln422Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA407447884"}}],"detectionMethod":"Sanger sequencing was conducted to validate candidate variants identified by WES and segregation analysis was performed in available family members.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0200106","obo:HP_0002643","obo:HP_0033036","obo:HP_0001696","obo:HP_0012263","obo:HP_0031245","obo:HP_0000246"],"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/817233bd-f55d-408d-a18b-f77638299c13_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31186518","allele":{"id":"https://genegraph.clinicalgenome.org/r/017eaa29-9f0d-4741-b511-cb5cc36db837"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"}},{"id":"https://genegraph.clinicalgenome.org/r/f8d78a55-e73a-44d0-af94-f505b57810c3_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31186518","allele":{"id":"https://genegraph.clinicalgenome.org/r/f10265d7-a1fa-4abd-90da-fbf69c3480a8"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"}}]}},"phenotypePositiveAllelePositive":1,"phenotypes":["obo:HP_0012263","obo:HP_0001696","obo:HP_0000246","obo:HP_0012256","obo:HP_0002643","obo:HP_0033036"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/c9fd6ff8-b0b3-4883-b298-b0f81fa381bf"}},{"id":"https://genegraph.clinicalgenome.org/r/96aa4e70-4ddb-4750-babc-080c56475792_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22387996","rdfs:label":"UCL66/67","estimatedLodScore":2.18,"family":{"id":"https://genegraph.clinicalgenome.org/r/96aa4e70-4ddb-4750-babc-080c56475792","type":"Family","rdfs:label":"UCL66/67","ethnicity":{"id":"cg:NotHispanicOrLatino"},"member":{"id":"https://genegraph.clinicalgenome.org/r/54e935fd-29b8-4c2f-8970-19ef238a7345","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22387996","rdfs:label":"UCL66/67-IV.2","allele":{"id":"https://genegraph.clinicalgenome.org/r/a5b1ff92-449b-47bb-bc9e-6e5b942ee88e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001256715.2(DNAAF3):c.265C>T (p.Arg89Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA025069"}},"detectionMethod":"All 12 coding exons of DNAAF3 were amplified from genomic DNA.  PCD families were also SNP haplotyped across the DNAAF3 locus. ","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Linkage analysis","phenotypes":["obo:HP_0002783","obo:HP_0000246","obo:HP_0031417","obo:HP_0000388","obo:HP_0002643","obo:HP_0012263","obo:HP_0002110","obo:HP_0012735"],"previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/a9651102-b0c9-4b23-b49b-cd8454cedaef_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22387996","allele":{"id":"https://genegraph.clinicalgenome.org/r/a5b1ff92-449b-47bb-bc9e-6e5b942ee88e"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}}},"meetsInclusionCriteria":true,"phenotypeNegativeAlleleNegative":3,"phenotypePositiveAllelePositive":4,"phenotypes":["obo:HP_0012735","obo:HP_0012263","obo:HP_0002110","obo:HP_0011950","obo:HP_0000246","obo:HP_0000388","obo:HP_0000365","obo:HP_0031417","obo:HP_0002783","obo:HP_0002643","obo:HP_0001696"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/54e935fd-29b8-4c2f-8970-19ef238a7345"},"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/ee40a5ae-6e77-4c43-8ef4-b348b2939ce9_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22387996","rdfs:label":"UCL71","estimatedLodScore":0.73,"family":{"id":"https://genegraph.clinicalgenome.org/r/ee40a5ae-6e77-4c43-8ef4-b348b2939ce9","type":"Family","rdfs:label":"UCL71","ethnicity":{"id":"cg:NotHispanicOrLatino"},"member":{"id":"https://genegraph.clinicalgenome.org/r/02ffcc2a-fece-466f-b6bc-8ddf9699b90e","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22387996","rdfs:label":"UCL71-IV.2","allele":{"id":"https://genegraph.clinicalgenome.org/r/2d020b0f-db64-493f-945a-77cd7408de54"},"detectionMethod":"All 12 coding exons of DNAAF3 were amplified from genomic DNA.  PCD families were also SNP haplotyped across the DNAAF3 locus. ","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Linkage analysis","phenotypes":["obo:HP_0001696","obo:HP_0100582","obo:HP_0002110","obo:HP_0000246","obo:HP_0012735","obo:HP_0031417","obo:HP_0002643","obo:HP_0030828","obo:HP_0000388","obo:HP_0002783","obo:HP_0012263"],"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/bf133165-4d4a-455a-9489-1e10881eba98_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22387996","allele":{"id":"https://genegraph.clinicalgenome.org/r/2d020b0f-db64-493f-945a-77cd7408de54"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}}},"meetsInclusionCriteria":false,"phenotypeNegativeAlleleNegative":1,"phenotypePositiveAllelePositive":2,"phenotypes":["obo:HP_0002110","obo:HP_0000246","obo:HP_0030828","obo:HP_0001696","obo:HP_0031417","obo:HP_0100582","obo:HP_0002783","obo:HP_0012735","obo:HP_0000388","obo:HP_0012263","obo:HP_0002643"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/02ffcc2a-fece-466f-b6bc-8ddf9699b90e"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/c9fd6ff8-b0b3-4883-b298-b0f81fa381bf_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/817233bd-f55d-408d-a18b-f77638299c13","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/817233bd-f55d-408d-a18b-f77638299c13_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_001256715.2(DNAAF3):c.238del, referred to by authors as NM_001256714.1:c.442del (NP_001243643.1:p.Leu148TrpfsTer13) is a frameshift mutation predicted to replace Leu148 with Trp and a termination signal 13 amino acids downstream, prematurely truncating 85% of the protein product. RT-PCR of proband RNA from nasal epithelial cells confirmed the presence of variant cDNA in this individual. TEM of respiratory cell cilia to view dynein arms produced equivocal results.  High resolution IF analysis with DNAH5 antibodies, however, confirmed the absence of ODA.  HSVA showed immotile cilia.","functionalDataSupport":"No"},{"id":"https://genegraph.clinicalgenome.org/r/817233bd-f55d-408d-a18b-f77638299c13_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/f8d78a55-e73a-44d0-af94-f505b57810c3","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f8d78a55-e73a-44d0-af94-f505b57810c3_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_001256715.2(DNAAF3):c.1264C>T, referred to by authors as NM_001256714.1:c.1465C>T\t(NP_001243643.1:p.Gln489Ter)  is a nonsense mutation predicted to replace Gln489 with a termination signal, prematurely truncating 22% of the protein product or triggering nonsense-mediated decay. TEM of respiratory cell cilia to view dynein arms produced equivocal results.  High resolution IF analysis with DNAH5 antibodies, however, confirmed the absence of ODA.  HSVA showed immotile cilia.","functionalDataSupport":"No"},{"id":"https://genegraph.clinicalgenome.org/r/f8d78a55-e73a-44d0-af94-f505b57810c3_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/c9fd6ff8-b0b3-4883-b298-b0f81fa381bf"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/beaf830f-971e-4bd7-89a0-dc9408cf97bb_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/638b2d11-5e16-41af-ae69-ad0bb4a2a181","type":"EvidenceLine","dc:description":"Score was down-graded to 1 because of homozygosity.","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/638b2d11-5e16-41af-ae69-ad0bb4a2a181_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_001256715.2(DNAAF3):c.162_164delinsG is a frameshift mutation predicted to replace Val 55 with Gly and a termination signal 28 amino acids downstream, prematurely truncating 90% of the protein product or triggering nonsense-mediated decay.  ","functionalDataSupport":"No"},{"id":"https://genegraph.clinicalgenome.org/r/638b2d11-5e16-41af-ae69-ad0bb4a2a181_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33479112","allele":{"id":"https://genegraph.clinicalgenome.org/r/ad8dba07-cdf8-4549-96df-aaa47dc0f011","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001256715.2(DNAAF3):c.162_164delinsG (p.Val55GlyfsTer28)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2573051126"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/beaf830f-971e-4bd7-89a0-dc9408cf97bb","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33479112","rdfs:label":"01-113","allele":{"id":"https://genegraph.clinicalgenome.org/r/ad8dba07-cdf8-4549-96df-aaa47dc0f011"},"detectionMethod":"Next-generation sequencing performed either by whole exome sequencing (WES) or targeted gene panel sequencing (Illumina TruSeq Custom Amplicon, Agilent SureSelect Focused Exome or SureSelectXT custom panel), including all known PCD genes and other candidate genes.\n\nVariants were confirmed by Sanger sequencing with parental segregation. For a number of patients, variants were identified by candidate gene Sanger sequencing.","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"DNAAF3 variant patients in this study were stratified into a group comprised of other patients with variants in genes that are involved in dynein assembly. As a group, these patients share diagnostic characteristics including: decreased nasal nitric oxide, ODA and IDA defects, microtubular disorganization, lack of cilia, and immotile or stiff cilia. Some of these characteristics may not be specific to DNAAF3.","previousTesting":false,"secondTestingMethod":"Next generation sequencing panels","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/638b2d11-5e16-41af-ae69-ad0bb4a2a181_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/e7c861de-a850-4ff0-866e-a0bbcad5f63b_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e9861c3a-e89e-44e0-8db6-86cbe19285a2","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e9861c3a-e89e-44e0-8db6-86cbe19285a2_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NC_000019.10:g.55165798_55165902del, referred to by authors as NM_001256714.1:c.388_432+60del, contains a 104 bp deletion that spans 44 bp of exon 3 and 60 bp of intron 3, including the donor splice site.  TEM of respiratory cell cilia to view dynein arms confirmed the absence of ODA and IDA. HSVA showed immotile cilia. ","functionalDataSupport":"No"},{"id":"https://genegraph.clinicalgenome.org/r/e9861c3a-e89e-44e0-8db6-86cbe19285a2_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/06e4bdbe-3659-49d8-8e9a-bf2e53ce5525","type":"EvidenceLine","dc:description":"This variant was already scored in individual P3 IV-2.  There is no evidence available to support that this variant has arisen in different populations or that these cases are not related so this variant has only been scored in the first proband, P3 IV-2.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/06e4bdbe-3659-49d8-8e9a-bf2e53ce5525_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_001256715.2(DNAAF3):c.607_611dup, referred to by authors as NM_001256714.1:c.811_815dup (NP_001243643.1:p.Arg273ThrfsTer13), is a frameshift mutation caused by a 5bp duplication.  This variant is predicted to replace Arg273 with Thr and introduce a termination 13 amino acids downstream, truncating the protein product by 62% or triggering non-sense mediated decay.  TEM of respiratory cell cilia to view dynein arms confirmed the absence of ODA and IDA. HSVA showed immotile cilia. ","functionalDataSupport":"No"},{"id":"https://genegraph.clinicalgenome.org/r/06e4bdbe-3659-49d8-8e9a-bf2e53ce5525_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/e7c861de-a850-4ff0-866e-a0bbcad5f63b"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/9a361dea-9024-4b65-af98-844a906bffc1_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6ab9c56e-e407-4bce-a11a-1902f9c8123d","type":"EvidenceLine","calculatedScore":0.2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6ab9c56e-e407-4bce-a11a-1902f9c8123d_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_001256715.2(DNAAF3):c.228+5G>C is a splice site mutation in intron 3 of the DNAAF3 gene, predicted by the SplceA1 algorithm to disrupt the consensus donor splice site at a highly conserved G residue.","functionalDataSupport":"No"},{"id":"https://genegraph.clinicalgenome.org/r/6ab9c56e-e407-4bce-a11a-1902f9c8123d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33479112","allele":{"id":"https://genegraph.clinicalgenome.org/r/a773286d-9d8f-414f-8d71-10e49f01511c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001256715.2(DNAAF3):c.228+5G>C","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA9668206"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/9a361dea-9024-4b65-af98-844a906bffc1","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33479112","rdfs:label":"01-185","allele":{"id":"https://genegraph.clinicalgenome.org/r/a773286d-9d8f-414f-8d71-10e49f01511c"},"detectionMethod":"Next-generation sequencing performed either by whole exome sequencing (WES) or targeted gene panel sequencing (Illumina TruSeq Custom Amplicon, Agilent SureSelect Focused Exome or SureSelectXT custom panel), including all known PCD genes and other candidate genes.\n\nVariants were confirmed by Sanger sequencing with parental segregation. For a number of patients, variants were identified by candidate gene Sanger sequencing.","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"DNAAF3 variant patients in this study were stratified into a group comprised of other patients with variants in genes that are involved in dynein assembly. As a group, these patients share diagnostic characteristics including: decreased nasal nitric oxide, ODA and IDA defects, microtubule disorganization, lack of cilia, and immotile or stiff cilia. Some of these characteristics may not be specific to DNAAF3.","previousTesting":false,"secondTestingMethod":"Next generation sequencing panels","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/6ab9c56e-e407-4bce-a11a-1902f9c8123d_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/0b503c84-43f4-4043-9544-2348fc4fe329_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/82c2fbbd-3a0d-4b91-80b4-4ef3dc28ffdf","type":"EvidenceLine","calculatedScore":0.2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/82c2fbbd-3a0d-4b91-80b4-4ef3dc28ffdf_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NC_000019.10:g.55166019G>T, referred to by authors as NM_001256714.1:c.271C>A (NP_001243643.1:p.Pro91Thr),  is a missense mutation that replaces Pro91 with Thr in the 608 amino acid DNAAF isoform 1 (NM_001256714.1). The Polyphen-2 algorithm predicts that this alteration is probably damaging.  The Provean algorithm found this to be a neutral substitution.  This amino acid residue is not present in isoforms 2 or 3 of DNAAF3 (NM_178837.4, NM_001256715.2).  This variant is not found in gnomAD.","functionalDataSupport":"No"},{"id":"https://genegraph.clinicalgenome.org/r/82c2fbbd-3a0d-4b91-80b4-4ef3dc28ffdf_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33577779","allele":{"id":"https://genegraph.clinicalgenome.org/r/0caedd14-36d1-4d70-b6e4-990a6b6116c1","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000019.10:g.55166019G>T (GRCh38)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA407461988"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/0b503c84-43f4-4043-9544-2348fc4fe329","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33577779","rdfs:label":"P11","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":9,"allele":{"id":"https://genegraph.clinicalgenome.org/r/0caedd14-36d1-4d70-b6e4-990a6b6116c1"},"ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0001742","obo:HP_0033036","obo:HP_0000246","obo:HP_0002099","obo:HP_0031245","obo:HP_0012259","obo:HP_0002110","obo:HP_0100750"],"previousTesting":false,"sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/82c2fbbd-3a0d-4b91-80b4-4ef3dc28ffdf_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/54e935fd-29b8-4c2f-8970-19ef238a7345_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a9651102-b0c9-4b23-b49b-cd8454cedaef","type":"EvidenceLine","dc:description":"Down-scored to 0.5 because of parental consanguinity and variant homozygosity.  It has been further down-scored to 0.25 because the genotyping method was Sanger sequencing and mutations in other PCD genes were not excluded.","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a9651102-b0c9-4b23-b49b-cd8454cedaef_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_001256715.2(DNAAF3):c.265C>T, referred to by authors as NM_178837.4:c.406C>T\t(NP_849159.2:p.Arg136Ter), is a nonsense mutation predicted to replace Arg136 with a termination signal, prematurely truncating 84% of the protein or triggering nonsense-mediated mRNA decay. Nasal respiratory cells were shown to have immotile cilia.","functionalDataSupport":"No"},{"id":"https://genegraph.clinicalgenome.org/r/a9651102-b0c9-4b23-b49b-cd8454cedaef_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/54e935fd-29b8-4c2f-8970-19ef238a7345"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/16c83f0c-7d70-40f9-b960-951eda18ce21_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/678151b5-a7c2-4471-aab2-b8fd0bd89a07","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/678151b5-a7c2-4471-aab2-b8fd0bd89a07_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_001256715.2(DNAAF3):c.570G>A is a nonsense mutation predicted to replace Trp 190 with a termination signal, prematurely truncating 65% of the protein product or triggering nonsense-mediated decay. ","functionalDataSupport":"No"},{"id":"https://genegraph.clinicalgenome.org/r/678151b5-a7c2-4471-aab2-b8fd0bd89a07_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33479112","allele":{"id":"https://genegraph.clinicalgenome.org/r/4e8f407c-14db-4589-a36b-8b085e72c0be","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001256715.2(DNAAF3):c.570G>A (p.Trp190Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA407455296"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/140ed212-ddab-4173-a51e-e48c04a94d38","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/140ed212-ddab-4173-a51e-e48c04a94d38_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_001256715.2(DNAAF3):c.997dup is a frameshift mutation predicted to replace Asp 333 with Gly and a termination signal 64 amino acids downstream, prematurely truncating 38% of the protein product or triggering nonsense-mediated decay. ","functionalDataSupport":"No"},{"id":"https://genegraph.clinicalgenome.org/r/140ed212-ddab-4173-a51e-e48c04a94d38_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33479112","allele":{"id":"https://genegraph.clinicalgenome.org/r/39230854-7ed4-4973-8cd9-1d4136206193","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001256715.2(DNAAF3):c.997dup (p.Asp333fs)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA9667979"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/16c83f0c-7d70-40f9-b960-951eda18ce21","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33479112","rdfs:label":"01-070","allele":[{"id":"https://genegraph.clinicalgenome.org/r/4e8f407c-14db-4589-a36b-8b085e72c0be"},{"id":"https://genegraph.clinicalgenome.org/r/39230854-7ed4-4973-8cd9-1d4136206193"}],"detectionMethod":"Next-generation sequencing performed either by whole exome sequencing (WES) or targeted gene panel sequencing (Illumina TruSeq Custom Amplicon, Agilent SureSelect Focused Exome or SureSelectXT custom panel), including all known PCD genes and other candidate genes.\n\nVariants were confirmed by Sanger sequencing with parental segregation. For a number of patients, variants were identified by candidate gene Sanger sequencing.","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"DNAAF3 variant patients in this study were stratified into a group comprised of other patients with variants in genes that are involved in dynein assembly. As a group, these patients share diagnostic characteristics including: decreased nasal nitric oxide, ODA and IDA defects, microtubule disorganization, lack of cilia, and immotile or stiff cilia. Some of these characteristics may not be specific to DNAAF3.","previousTesting":false,"secondTestingMethod":"Next generation sequencing panels","sex":"UnknownEthnicity","variant":[{"id":"https://genegraph.clinicalgenome.org/r/678151b5-a7c2-4471-aab2-b8fd0bd89a07_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/140ed212-ddab-4173-a51e-e48c04a94d38_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3.0},{"id":"https://genegraph.clinicalgenome.org/r/02ffcc2a-fece-466f-b6bc-8ddf9699b90e_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bf133165-4d4a-455a-9489-1e10881eba98","type":"EvidenceLine","dc:description":"Down-scored because of parental consanguinity and variant homozygosity. It has been further down-scored to 0.25 because the genotyping method was Sanger sequencing and mutations in other PCD genes were not excluded.","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bf133165-4d4a-455a-9489-1e10881eba98_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_001256715.2(DNAAF3):c.621dup, referred to by authors as NM_178837.4:c.762dup\t(NP_849159.2:p.Val255CysfsTer12), is a frameshift variant predicted to replace Val255 with Cys and a termination signal 12 amino acids downstream, prematurely truncating 62% of the protein product or triggering nonsense-mediated decay. Nasal respiratory cells were shown to have immotile cilia.","functionalDataSupport":"No"},{"id":"https://genegraph.clinicalgenome.org/r/bf133165-4d4a-455a-9489-1e10881eba98_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/02ffcc2a-fece-466f-b6bc-8ddf9699b90e"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/40329b6f-2d65-49dd-863b-f79dcd1b5a23_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/40329b6f-2d65-49dd-863b-f79dcd1b5a23_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1cc29bd5-74a3-42d3-8518-0fd6240fe23e","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3f0c2ce1-8891-4607-87f8-87ed491a7d88","type":"Finding","dc:description":"Morpholino-mediated knockdown of dnaaf3 in zebrafish disrupted dynein assembly and caused loss of ciliary motility in several tissues.  The morphology and number of cilia in the olfactory placode of morphant fish was normal, but the reduction and absence of both ODAs and IDAs in these cilia is consistent with the role of zebrafish dnaaf3 and human DNAAF3 in the assembly of axonemal dyneins. The loss of motility in olfactory placode cilia recapitulates the immotile nasal cilia seen in humans with DNAAF3 mutations. Ciliary motility provides essential developmental signals during embryogenesis in humans and zebrafish.  Morphant fish with axis curvature defects and laterality defects parallel the laterality defects seen in human DNAAF3 patients.  Hydrocephalus, perturbed otolith development, and the development of pronephric (kidney) cysts are zebrafish phenotypes consistent with the loss of ciliary motility, a loss of function consistent  with human PCD.\n\nIn situ hybridization of wild type embryos with dnaaf3 specific probes show expression in the ciliated cells of the spinal cord floor plate, the olfactory placodes, pronephros, and lateral line organs.  These are all motile ciliated structures in zebrafish (PMID: 34445067).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22387996","rdfs:label":"Morpholino knockdown of dnaaf3 in zebrafish embryos","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/af1dc4ab-d452-4d03-8757-7197af986d78","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/aabfff2f-1e27-42e8-8958-9faf95696c39","type":"Finding","dc:description":"RNAi depletion and CRISPR-generated null alleles of Drosophila Dnaaf3 specifically exhibit phenotypes consistent with ciliary/flagellar immotility with loss of both ODA and IDA, depletion of of dynein heavy chains, and the absence of DNAH5 in mutant motile cilia. Male infertility, immotile sperm, and the loss of auditory/vibration mechanotransduction in Ch neurons in null Dnaaf3 mutants in Drospohila are phenotypes consistent with the human DNAAF3 mutations that result in cilial immotility in respiratory cells resulting in respiratory symptoms and infertility caused by cilial and flagellar defects in reproductive cells (Fallopian tubes, efferent ducts, sperm).  Human DNAAF3 mutations have also been shown to result in the absence of inner and outer dynein arms and have been associated with the loss of dynein proteins (DNAH5 and DNALI1) in respiratory cilia (PMID: 22387996).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34553759","rdfs:label":"Drosophila Dnaaf3 required for dynein motor pre-assembly","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/41ae8add-1205-4962-b440-987b4ba64b8f","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8a333cd7-e8f2-479e-8215-842318201758","type":"Finding","dc:description":"Transformation of pf22 mutant  Chlamydomonas with wild type copies of pf22 rescues the pf22 phenotype of short flagella, lack of motility and dynein assembly defects. Assembly of all three missing flagellar dyneins (DHC5, DHC9, and IC2) is rescued by transformation with untagged or Myc-tagged wild type copies of the pf22 gene.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22387996","rdfs:label":"Chlamydomonas PF22 rescue experiment","demonstrates":{"id":"cg:PhenotypeRescue"}}],"specifiedBy":"GeneValidityNonHumanRescueCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4},{"id":"https://genegraph.clinicalgenome.org/r/40329b6f-2d65-49dd-863b-f79dcd1b5a23_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4df44e6a-760e-42e5-bdfe-451b89c12b91","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/be518222-16f0-410e-9a15-76aee67df7d7","type":"FunctionalAlteration","dc:description":"Transmission electron microscopy of representative cilia cross sections from respiratory epithelial cells of sibling PCD patients (UCL89) show a loss of both outer and inner dynein arms.  Additionally, immunofluorescence to further characterize cilia structure in these cells showed an absence of DNAH5, DNAH9 and DNAI2 (outer dynein arm components)  and an absence of the inner dynein arm component DNALI1. The absence of these dyneins suggests a disruption of outer and inner dynein arm assembly in the airway of patients carrying DNAAF3 mutations.  Reduced amounts of DNAH5 in the apical cytoplasm in one of the DNAAF3 patient cells, suggests that some outer row dynein proteins  are present in a form that cannot assemble into cilia.  These data are consistent with DNAAF3 assisting in the cytoplasmic assembly of axonemal dyneins.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22387996","rdfs:label":"Structural defects in respiratory cilia from DNAAF3 patients"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/40329b6f-2d65-49dd-863b-f79dcd1b5a23_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/61a0f2c4-2f70-43fc-a195-d2f38ab3abdb","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/89e7bff0-0466-4054-a3c3-26b4d5fd3eab","type":"Finding","dc:description":"PCD can arise from mutations in genes encoding any of an array of cytoplasmic proteins collectively known as dynein axonemal assembly factors, DNAAFs, that help preassemble axonemal dynein motors in the cytoplasm before deployment to cilia (PMID: 32943623). Huizar et al., 2018 show that in Xenopus embryos DNAAFs concentrate together with axonemal dyneins and chaperones into organelles that form specifically in multiciliated cells, which they term DynAPs, for dynein axonemal particles.  Laser scanning confocal  microscopy showed that GFP-Dnaaf3 protein co-localized with Cherry-Dnaaf2 (Ktu) at DynAPs. (Dnaaf4, Dnaaf5, Dnaaf6, Spag1, Dnaaf11, Zmynd10 also co-localized with Cherry-Dnaaf2 (Ktu) as did the dynein subunits Dnai1, Dnai2, and DNAli1). A 3D object-based co-localization algorithm was used to quantify co-localization data of GFP-fusion proteins to cherry-Ktu.  The co-localization of DnaaFf3 with various DNAAFs in DynaPs is consistent with the role of DNAAF3 being part of a cytoplasmic multiprotein complex that assembles inner and outer dynein arm components.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30561330","rdfs:label":"Co-localization of Dnaaf3 with dynein assembly proteins","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/fd825797-7115-48e6-a4e5-65409baba410","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0b39d69b-e456-44ed-873e-db630491e3d3","type":"Finding","dc:description":"DNAAF3 (HS351582 in this study) was identified as 1 of 89 genes that were significantly down-related in the testicular tissue of patients with Sertoli cell-only syndrome (SCOS), a cause of male infertility.  Semiquantitative RT-PCR confirmed that DNAAF3 was present in the testes of normal patients but down-regulated in those of SCOS patients.  These results were followed up with a study of the expression patterns (Clontech Human Total RNA Panel) of these novel genes in  normal mice and humans.  RT-PCR showed expression of DNAAF3 (HS351582) in human testis and the expression of its mouse ortholog (m247538) in lung, testis and ovary. The expression of DNAAF3 in human testis is consistent with the phenotype of male infertility associated with PCD in patients with DNAAF3 mutations (PMIDs: 31781811, 22387996).  The expression of murine Dnaaf3 in mouse lung, testis and ovary is consistent with the role DNAAF3 is thought to play in the assembly of inner and outer dynein arms in respiratory cilia, sperm, cilia in male efferent ducts, and cilia in Fallopian tubes (PMID:32943623).\n\nNote:  Lin et al. (2006) mapped the DNAAF3 (Hs351582) gene to chromosome 19q13.4, predicted a 12 exon gene structure, a 2.2 kb transcript, and a 608 amino acid protein product.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17074343","rdfs:label":"DNAAF3 expression in human and mouse tissues","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/d51ee462-30e9-4a81-b1fb-1d4bd71972c3","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1766d526-593e-4d19-8d8e-8915363cf771","type":"Finding","dc:description":"The Genotype-Tissue Expression (GTEx) project has established a resource database and associated tissue bank for the scientific community to study the relationship between genetic variation and gene expression in human tissues. RNA-seq expression studies were performed on 54 reference tissues. Bulk tissue gene expression for DNAAF3 shows the expression of  DNAAF3 in lung, testis, and Fallopian tube. This pattern is consistent with the role DNAAF3 is thought to play in the assembly of inner and outer dynein arms in respiratory cilia, sperm, cilia in male efferent ducts, and cilia in Fallopian tubes (PMID:32943623).\n","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23715323","rdfs:label":"GTEx DNAAF3 gene expression","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6}],"evidenceStrength":"Definitive","sequence":4363,"specifiedBy":"GeneValidityCriteria8","strengthScore":18,"subject":{"id":"https://genegraph.clinicalgenome.org/r/zQoeNOOCzk0","type":"GeneValidityProposition","disease":"obo:MONDO_0011718","gene":"hgnc:30492","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_40329b6f-2d65-49dd-863b-f79dcd1b5a23-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}